Gates Package — page 1039
of 1375 pages
← p.1038 p.1040 → · this page in the original PDF · package
or a single-use plastic bag--but the supplies of both are limited. Early in the
pandemic, bioreactors were bought up en masse by various companies hoping
for an early breakthrough. If you couldn't find toilet paper at the store, you
know how they felt.
Next, you'll mix your vaccine with other things to make it more effective or
stable. If it's an mRNA vaccine, you'll need a lipid. If it's another type, you
might need what's known as an adjuvant, a substance that sets off red alerts in
your immune system and shouts: "Hey, come look at this new shape over here!
You'd better learn to attack it." Believe it or not, one of the most effective
adjuvants in the world is derived from the inner bark from the Chilean
soapbark tree. Unfortunately, these trees are relatively rare, so your
manufacturing may be held up while you stand in line for your allotment of
bark. In the future, we need to be able to make synthetic versions of adjuvants
so we can scale up manufacturing quickly.
Finally, you'll need to pour your doses into vials. You'll need sterile, highly
precise equipment, and each part of the vials you use will have to meet
exacting specifications, down to the type of glass and stopper. (At one point
during COVID, there were fears that the world would run out of the high-grade
sand used to make the necessary glass.) You'll need to label your vials
according to rules set by the country in which you'll sell it, including which
This is our OCR of the page, with running headers and footers removed. The
Committee's PDF
is authoritative; quote from it. Machine-readable, including the uncleaned
text: /api/page/gates/1039
Records on this page
| Record | Date | Type | Pages |
|---|---|---|---|
| gates:exh:00449 | — | attachment | 1039 |